NCT04202965

PTG-300 in Subjects With Hereditary Hemochromatosis

Open-label Study of PTG-300 in Subjects With Hereditary Hemochromatosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Protagonist Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.

Detailed description

This study is a multicenter, open-label study. The objective of the study is to assess the effect of PTG-300 on transferrin saturation (TSAT) and serum iron in adult hereditary hemochromatosis patients.

Conditions

• Hereditary Hemochromatosis

Interventions

Type	Name	Description
DRUG	PTG-300	Active treatment with PTG-300 injected subcutaneously.

Timeline

• Start date: 2020-03-19
• Primary completion: 2021-10-06
• Completion: 2022-02-15
• First posted: 2019-12-18
• Last updated: 2025-08-20
• Results posted: 2023-06-15

Locations

11 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study